HC Wainwright Issues Optimistic Outlook for AKRO Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – HC Wainwright raised their Q1 2025 EPS estimates for Akero Therapeutics in a report released on Monday, March 3rd. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($0.96) per share for the quarter, up from their previous forecast of ($1.16). HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at ($4.55) EPS, FY2027 earnings at ($4.19) EPS, FY2028 earnings at ($2.95) EPS and FY2029 earnings at $2.67 EPS.

Several other research analysts have also recently weighed in on the stock. Citigroup boosted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. UBS Group boosted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Morgan Stanley boosted their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, Canaccord Genuity Group boosted their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $76.29.

Akero Therapeutics Stock Up 1.3 %

Akero Therapeutics stock opened at $45.13 on Thursday. Akero Therapeutics has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The stock has a market cap of $3.15 billion, a PE ratio of -12.03 and a beta of -0.19. The firm’s 50-day simple moving average is $39.92 and its 200 day simple moving average is $33.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01).

Institutional Trading of Akero Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AKRO. Creative Planning bought a new stake in Akero Therapeutics during the 3rd quarter worth approximately $371,000. Victory Capital Management Inc. bought a new stake in Akero Therapeutics during the 3rd quarter worth approximately $211,000. Simplify Asset Management Inc. increased its holdings in Akero Therapeutics by 15.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock worth $8,141,000 after acquiring an additional 38,279 shares during the period. LMR Partners LLP increased its holdings in Akero Therapeutics by 17.0% during the 3rd quarter. LMR Partners LLP now owns 20,597 shares of the company’s stock worth $591,000 after acquiring an additional 2,997 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Akero Therapeutics during the 3rd quarter worth approximately $491,000.

Insider Activity at Akero Therapeutics

In related news, CEO Andrew Cheng sold 7,855 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total transaction of $241,855.45. Following the sale, the chief executive officer now directly owns 597,562 shares in the company, valued at approximately $18,398,933.98. This represents a 1.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Patrick Lamy sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $48.09, for a total transaction of $48,090.00. Following the sale, the vice president now owns 33,492 shares in the company, valued at $1,610,630.28. The trade was a 2.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 224,992 shares of company stock worth $10,800,953. 7.94% of the stock is owned by corporate insiders.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.